UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ALVOTECH USA INC. AND ALVOTECH HF,
Petitioner,

v.

REGENERON PHARMACEUTICALS, INC.,
Patent Owner.

PGR2025-00085
Patent 12,168,036

DECLARATION OF DEANNA REICHEL

ALVOTECH 1076
Alvotech v. Regeneron
PGR2025-00085

I, Deanna Reichel, hereby declare to the following:

1. I am a member in good standing of the state Bar of Minnesota (SBN: 0326513), as well as the United States Court of Appeals for the Federal Circuit, and the Supreme Court of the United States, among other courts.

2. I have not been suspended or disbarred from practice before any court or administrative body.

3. I have never had an application for admission to practice before any court or administrative body denied.

4. No sanction or contempt citation has been imposed against me by any court or administrative body.

5. I have read and will comply with the Office Patent Trial Practice Guide and the Board's Rules of Practice for Trials set forth in Part 42 of Title 37 of the Code of Federal Regulations.

6. I will be subject to the USPTO Rules of Professional Conduct set forth in 37 C.F.R. §§ 11.101 *et seq.* and disciplinary jurisdiction under 37 C.F.R. § 11.19(a).

7. I am a provisionally recognized PTAB attorney. I have been previously recognized *pro hac vice* before the Patent Trial and Appeal Board in PGR2023-00020 and IPR2024-00580.

8. I am an experienced patent litigation attorney with more than 23 years of experience representing clients in cases involving a wide variety of pharmaceutical compounds, formulations, and treatment methods for medical conditions. I regularly litigate patent cases before the United States Court of Appeals for the Federal Circuit and various federal district courts.

9. I am intimately familiar with the issues and subject matter presented in this above-captioned post grant review proceeding. For example, I have extensively reviewed the above identified patent, its prosecution history, the Petition for PGR (including the invalidity grounds therein, and the cited references), and all exhibits filed in this case.

10. I have satisfied all requirements set forth by the Board for *pro hac vice* recognition of a provisionally recognized PTAB attorney.

11. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code.

Respectfully submitted,

Date: May 27, 2026

/Deanna Reichel/

DEANNA REICHEL
Fish & Richardson P.C.
Email: reichel@fr.com

APPENDIX A

FISH.



Deanna J. Reichel

Principal
Minneapolis
612 766 2037
reichel@fr.com

Overview

Repeatedly recognized as a leading litigator, Deanna Reichel deftly handles Hatch-Waxman and other life sciences litigation. She represents clients at trial and on appeal to the Federal Circuit and U.S. Supreme Court.

Deanna handles all phases of Hatch-Waxman and other life sciences cases, from the due diligence phase through trial and appeal, when necessary. She has litigated cases involving a wide variety of pharmaceutical compounds, formulations, and treatment methods for conditions such as glaucoma, hair loss, angina, and hepatitis C virus.

Deanna has tried cases in many different venues across the U.S., including in the Eastern District of Texas, the District of Delaware, the District of New Jersey, and the Northern District of California. She also has worked on numerous Federal Circuit and U.S. Supreme Court appeals and regularly leads briefing on those appeals. Her successes include securing the U.S. Supreme Court's unanimous reversal of a lower court ruling of patent infringement against client Mayo Collaborative Services.

Deanna also serves as the firm's recruiting principal for the Minneapolis office. In that role, she strives to advance the firm's diversity and inclusion programs and efforts.

Before joining the firm, she served as a law clerk for the Honorable Raymond Clevenger III of the U.S. Court of Appeals for the Federal Circuit (2002-2003).

Experience

Athena Diagnostics, Inc. v. Mayo Collaborative Services (D. Mass.): Represented Mayo in Federal Circuit and Supreme Court in patent case related to detection of autoimmune disorder in patients. After district court granted § 12(b)(6) dismissal under § 101; result upheld by Federal Circuit in high-profile appeal, and certiorari denied by Supreme Court.

Gilead Sciences v. Merck & Co, Inc. et al. (N.D. Cal.): Trial and appellate counsel for Gilead in action over Gilead's revolutionary hepatitis C drugs, Harvoni and Sovaldi. Fish won a unanimous Federal Circuit opinion that affirmed its June 2016 post-trial wipe-out of a $200 million jury verdict. Read about this historic win here and here.

Trial and appellate counsel for plaintiff in Hatch-Waxman action over Abbreviated New Drug Applications for glaucoma drug. Patents found infringed and not invalid, and injunction entered against generic entry in 2014. Affirmed by Federal Circuit on appeal.

Prometheus Laboratories v. Mayo Collaborative Services (S.D. Cal.): Appellate counsel for defendants in patent infringement action over metabolite assays for thiopurine drugs. After Federal Circuit reversed a summary judgment of invalidity under 35 U.S.C. § 101, Supreme Court unanimously reversed, finding that claims did not recite patent-eligible subject matter and were invalid under § 101.

Opinion at 566 U.S. 66 (2012).

Roche Palo Alto, et al v. Lupin, Ltd., et al (D.N.J.): Trial counsel for plaintiffs in Hatch-Waxman action over defendants' ANDA for angina drug Ranexa. After three-week bench trial in May 2013, case settled with Lupin agreeing to forestall entry until three months before patent expiry.

Trial and appellate counsel for leading pharmaceutical company in multi-district litigation regarding defendants' ANDAs for glaucoma drugs. Injunction entered against generic entry in October 2009 and affirmed by Federal Circuit on appeal.

Recognitions & awards

Best Lawyers in America

Best Lawyers 2025-2026

IAM Patent 1000

IAM 2023-2025

Attorney of the Year

Minnesota Lawyer 2020

Local Litigation Star

Benchmark Litigation 2020

Top 250 Women in Litigation

Benchmark Litigation 2018-2019

Insights

Blog | November 1, 2022
Limelight v. Akamai: A software case worthy of biotech's attention

Blog | April 2, 2020
Section 101: Cert. Denied ... Now What?

Webinar | February 20, 2020
Section 101: Cert. Denied...Now What?

Article | May 3, 2018
The Women Warriors Behind Gilead's Huge Federal Circuit Win

News

August 20, 2025
95 Fish Attorneys Included in the 2026 Edition of *The Best Lawyers in America*

May 30, 2025
Fish & Richardson Receives Top Rankings in 2025 Edition of *IAM Patent 1000: The World's Leading Patent Professionals*

August 15, 2024
101 Fish Attorneys Included in the 2025 Edition of *The Best Lawyers in America*

June 11, 2024
Fish & Richardson Receives Top Rankings in 2024 Edition of *IAM Patent 1000: The World's Leading Patent Professionals*

June 27, 2023
Fish & Richardson Receives Top Rankings in 2023 Edition of *IAM Patent 1000: The World's Leading Patent Professionals*

August 15, 2022
Fish & Richardson Secures Win for Exela Pharma Sciences in ELCYS® Patent Infringement Litigation

January 7, 2021
Fish & Richardson Receives 2020 "Attorney of the Year" Group Award from *Minnesota Lawyer*

August 20, 2019
Fish & Richardson Principals Juanita Brooks, Betsy Flanagan and Deanna Reichel Named to 2019 "Top 250 Women in Litigation" List

January 10, 2019
Fish & Richardson Obtains Denial of Cert at U.S. Supreme Court for Gilead Sciences in Long-Running Patent Battle with Merck Over Hepatitis C Drugs

August 6, 2018
Fish & Richardson Principals Juanita Brooks, Betsy Flanagan and Deanna Reichel Named to 2018 "Top 250 Women in Litigation" List

April 25, 2018
Fish & Richardson Wins Federal Circuit Affirmance of Reversal of $200 Million Damages Against Gilead After Merck's "Unclean Hands"

July 17, 2017
Fish & Richardson Elects Deanna Reichel as a Principal

November 17, 2016
Minneapolis Office Hosts Girl Scout Troops for IP Collaboration

---

Events

September 26, 2024
Midwest IP Institute 2024

June 23, 2021
Federal Circuit Bar Association's 2021 Bench & Bar® Conference

April 16, 2020
Patents on Tap | Patent Eligibility at the Supreme Court: What You Need to Know

September 26, 2019
2019 Midwest IP Institute - MIPLA

March 15, 2018
Patents on Tap | Do IPR Proceedings Violate the Constitution?

Services

Appellate
Litigation
Patent Litigation

Industries

Life Sciences
Energy & Chemicals

Admissions

Minnesota (2003)
Supreme Court of the United States
U.S. Court of Appeals for the Federal Circuit

Clerkships

U.S. Court of Appeals for the Federal Circuit, The Honorable Raymond C. Clevenger III (2002-2003)

Education

J.D. with highest distinction, Order of the Coif, University of Iowa College of Law (2002) Note & Comment Editor, *Journal of Corporation Law*

B.S. *summa cum laude*, Chemistry, University of St. Thomas (1999)

Copyright © 2026 Fish & Richardson P.C.